Results 91 to 100 of about 74,852 (258)

Membrane Fusion‐Mediated Cytosolic Delivery of Threose Nucleic Acids via Homotypic Nanoparticles Overcomes Drug Resistance in Triple‐Negative Breast Cancer

Advanced Science, EarlyView.
This study introduces a biomimetic “nanofusion” platform that integrates the biostability of threose nucleic acids (TNA) with homotypic cell‐membrane cloaking to combat drug‐resistant TNBC. By leveraging a non‐canonical membrane‐fusion pathway for direct cytosolic delivery, the platform bypasses endosomal sequestration. To achieve potent AKT2 silencing
Wei Zheng, Tristan Juin Han Chang, Xinchao Li, Zhongqi Zhou, Chung Tin, Kenward Vong, Pierre Karam, Pik Kwan Lo   +7 more
wiley   +1 more source

Combinations of PARP Inhibitors with Temozolomide Drive PARP1 Trapping and Apoptosis in Ewing's Sarcoma.

PLoS ONE, 2015
Ewing's sarcoma is a malignant pediatric bone tumor with a poor prognosis for patients with metastatic or recurrent disease. Ewing's sarcoma cells are acutely hypersensitive to poly (ADP-ribose) polymerase (PARP) inhibition and this is being evaluated in
Sonja J Gill, Jon Travers, Irina Pshenichnaya, Fiona A Kogera, Syd Barthorpe, Tatiana Mironenko, Laura Richardson, Cyril H Benes, Michael R Stratton, Ultan McDermott, Stephen P Jackson, Mathew J Garnett   +11 more
doaj   +1 more source

[PARP inhibitors: significant progress in cancer therapy]

, 2011
Poly(ADP-ribosyl)ation is a post-translational modification of proteins catalyzed by poly(ADP-ribose) polymerases (PARPs). In response to genotoxic stress, PARP-1 senses DNA breaks and through the synthesis of poly(ADP-ribose) restores genome integrity ...
Dantzer, F. (Françoise), Schreiber, Valérie, Dantzer, Françoise, Schreiber, V. (Valerie), Noel, G. (Georges), Noel, Georges   +5 more
core   +1 more source

TDP‐43 Aggregation: The Healthy‐Toxic Balance of the Prion‐Like Domain

Advanced Science, EarlyView.
TDP‐43 function relies on a delicate balance between reversible phase‐separated states and irreversible aggregation. Under physiological conditions, TDP‐43 forms dynamic droplets and oligomers that support normal cellular functions. In pathological contexts, this balance shifts toward aberrant aggregation, leading to toxic species.
Luca Zangrando, Emanuele Buratti, Francesca Paron   +2 more
wiley   +1 more source

Clinical approaches to overcome PARP inhibitor resistance

Molecular Cancer
PARP inhibitors have profoundly changed treatment options for cancers with homologous recombination repair defects, especially those carrying BRCA1/2 mutations.
Yutian Zou, Hanqi Zhang, Pangzhou Chen, Jiayi Tang, Siwei Yang, Christophe Nicot, Ziyun Guan, Xing Li, Hailin Tang   +8 more
doaj   +1 more source

Poly (ADP-Ribose) Polymerase-1 (PARP-1) Inhibitors in Diabetic Retinopathy: An Attractive but Elusive Choice for Drug Development

Pharmaceutics
Owing to its promiscuous roles, poly (ADP-ribose) polymerase-1 (PARP-1) is involved in various neurological disorders including several retinal pathologies.
Etelka Pöstyéni, Róbert Gábriel, Andrea Kovács-Valasek   +2 more
doaj   +1 more source

PARP inhibitors for cancer therapy

, 2005
Poly(ADP-ribose) polymerase 1 (PARP-1) is a zinc-finger DNA-binding enzyme that is activated by binding to DNA breaks. Poly(ADP-ribosyl)ation of nuclear proteins by PARP-1 converts DNA damage into intracellular signals that activate either DNA repair by ...
Curtin NJ
core  

Combination of PARP inhibitors with clinical radiotherapy

, 2015
Radiosensitisation of solid tumours by manipulation of the DNA damage response offers an opportunity to increase the effectiveness of radiotherapy in terms of enhanced local tumour control, better alleviation of symptoms and improved cure rates.
Ross Carruthers, Anthony J Chalmers, Carruthers, Ross, Chalmers, Anthony   +3 more
core   +1 more source

NAD+ Metabolism Licenses Zygotic Genome Activation via PARP7‐Mediated ADP‐Ribosylation of UHRF1 in Mouse Early Embryos

Advanced Science, EarlyView.
This study uncovers a metabolic‐epigenetic axis licensing zygotic genome activation (ZGA) in mouse embryos. A developmental decline in NAD+ levels activates PARP7, which mono‐ADP‐ribosylates and stabilizes UHRF1. This modification promotes the establishment of permissive histone acetylation marks, thereby facilitating timely ZGA.
Guangyi Cao, Ziqi Zhang, Anqi Chen, Yanbo Liu, Yuling Lin, Lina Yu, Ruixin Shi, Aolei Guo, Yan Mao, Ganggui Lou, Chaojun Li, Luhong Wen, Guijun Yan, Haixiang Sun   +13 more
wiley   +1 more source

PARP inhibitors: beyond maintenance therapy

Within the last decade, the development and approval of PARP inhibitors have revolutionised the treatment landscape for many individuals living with cancer.
Phan, Zoe ; https://orcid.org/
core   +1 more source